Dr. Thomas joined the company in November 2011 as executive director, Regulatory Affairs, and was promoted to vice president, Regulatory Affairs and Medical Writing, in October 2012. She has more than 25 years of pharma and biopharma industry experience, with expertise in toxicology, project leadership and regulatory affairs. Prior to Sunesis, Dr. Thomas was vice president, Regulatory Affairs at BiPar Sciences, and previously served in various management positions in non-clinical development and regulatory affairs at Genentech, Inc.
“Debbie is a recognized leader at Sunesis with global responsibility for all regulatory and, more recently, quality assurance aspects of the pipeline programs,” said Daniel Swisher, chief executive officer of Sunesis. “I am pleased to announce this well-deserved promotion, particularly at a time when Sunesis is focused on reaching several key upcoming milestones through the ongoing review of vosaroxin’s Marketing Authorization Application in Europe and non-clinical and regulatory support for our emerging kinase pipeline programs to achieve meaningful clinical data. We look forward to her continued significant contributions to the company.”